Unnamed: 0,title,date,stock,sentiment
98239.0,"RBC Capital Initiates Coverage On Arrowhead Pharmaceuticals with Outperform Rating, Announces Price Target of $62",2020-05-13 04:59:00-04:00,ARWR,neutral
98240.0,17 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-05-08 07:50:00-04:00,ARWR,neutral
98241.0,Arrowhead Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 sales results.,2020-05-08 07:18:00-04:00,ARWR,positive
98242.0,"Cantor Fitzgerald Reiterates Overweight on Arrowhead Pharmaceuticals, Lowers Price Target to $58",2020-05-08 07:02:00-04:00,ARWR,negative
98243.0,Arrowhead Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 sales results.,2020-05-07 17:02:00-04:00,ARWR,positive
98244.0,"Arrowhead Pharmaceuticals Q2 EPS $(0.200) Misses $(0.110) Estimate, Sales $23.528M Beat $21.740M Estimate",2020-05-07 16:01:00-04:00,ARWR,negative
98245.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,ARWR,negative
98246.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,ARWR,neutral
98247.0,Arrowhead Pharmaceuticals Announces Retirement Of COO Bruce Given,2020-05-01 16:00:00-04:00,ARWR,neutral
98248.0,"Benzinga's Top Upgrades, Downgrades For April 15, 2020",2020-04-15 09:39:00-04:00,ARWR,positive
98249.0,"Arrowhead Pharmaceuticals shares are trading higher after Cantor Fitzgerald upgraded the stock from Neutral to Overweight and announced a price target of $60 per share. UPDATE: Shares have since reversed, now lower.",2020-04-15 08:09:00-04:00,ARWR,positive
98250.0,"Cantor Fitzgerald Upgrades Arrowhead Pharmaceuticals to Overweight, Announces $60 Price Target",2020-04-15 07:49:00-04:00,ARWR,negative
98251.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,ARWR,positive
98252.0,SVB Leerink Upgrades Arrowhead Pharmaceuticals to Market Perform,2020-03-24 06:50:00-04:00,ARWR,neutral
98253.0,Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.,2020-03-23 11:31:00-04:00,ARWR,negative
98254.0,Arrowhead Pharma Reports Precautionary Measures To Mitigate Effects Of Coronavirus Spread,2020-03-17 16:11:00-04:00,ARWR,neutral
98255.0,"Goldman Sachs Initiates Coverage On Arrowhead Pharmaceuticals with Neutral Rating, Announces $45 Price Target",2020-03-17 05:57:00-04:00,ARWR,neutral
98256.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 09:40:00-04:00,ARWR,negative
98257.0,"B. Riley FBR Maintains Buy on Arrowhead Pharmaceuticals, Lowers Price Target to $57",2020-03-13 07:32:00-04:00,ARWR,negative
98258.0,Shares of several healthcare  companies are trading lower. Movement appears market-related as markets continue to dip amid the global coronavirus outbreak and OPEC failing to reach production agreement.,2020-03-09 10:55:00-04:00,ARWR,neutral
98259.0,52 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-03-09 08:04:00-04:00,ARWR,neutral
98260.0,Shares of several healthcare companies are trading lower. Movement appears market related as markets continue to dip amid the global coronavirus outbreak.,2020-03-06 09:11:00-05:00,ARWR,neutral
98261.0,"Arrowhead Pharma Reports Initiation Of Phase 1/2 Study Of ARO-HSD In Normal Healthy Volunteers, Patients with NASH, Suspected NASH",2020-03-03 07:31:00-05:00,ARWR,positive
98262.0,Arrowhead Pharmaceuticals shares are trading higher. Not currently seeing company-specific news.,2020-02-26 11:04:00-05:00,ARWR,positive
98263.0,30 Stocks Moving in Tuesday's Pre-Market Session,2020-02-18 07:13:00-05:00,ARWR,neutral
98264.0,Arrowhead Pharmaceuticals shares are trading higher. Not seeing any company-specific news to justify the price action.,2020-02-10 11:41:00-05:00,ARWR,positive
98265.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,ARWR,negative
98266.0,"Cantor Fitzgerald Maintains Neutral on Arrowhead Pharmaceuticals, Raises Price Target to $55",2020-02-06 07:36:00-05:00,ARWR,neutral
98267.0,"Arrowhead Pharma Highlights Interim Data On ARO-APOC3, ARO-ANG3",2020-02-05 16:00:00-05:00,ARWR,neutral
98268.0,"Arrowhead Pharmaceuticals Q1 EPS $(0.03) Misses $(0.01) Estimate, Sales $29.45M Miss $29.5M Estimate",2020-02-05 16:00:00-05:00,ARWR,negative
98269.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,ARWR,neutral
98270.0,Arrowhead Pharmaceuticals shares are trading higher in sympathy with the overall market on a rebound after increased fear of the coronavirus' impact on the economy dropped the Dow roughly 600 points on Friday.,2020-02-03 10:37:00-05:00,ARWR,positive
98271.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,ARWR,neutral
98272.0,82 Biggest Movers From Yesterday,2020-01-22 04:18:00-05:00,ARWR,neutral
98273.0,Mid-Afternoon Market Update: CSS Industries Surges Following Acquisition News; Advaxis Shares Slide,2020-01-21 15:05:00-05:00,ARWR,positive
98274.0,55 Stocks Moving In Tuesday's Mid-Day Session,2020-01-21 12:14:00-05:00,ARWR,neutral
98275.0,Mid-Day Market Update: Dow Falls Over 100 Points; Genprex Shares Spike Higher,2020-01-21 12:07:00-05:00,ARWR,positive
98276.0,"SVB Leerink Initiates Coverage On Arrowhead Pharmaceuticals with Underperform Rating, Announces $32 Price Target",2020-01-21 09:08:00-05:00,ARWR,neutral
98277.0,Arrowhead Pharmaceuticals shares are trading lower. Not seeing any company-specific news to justify the price action.,2020-01-21 08:56:00-05:00,ARWR,neutral
98278.0,20 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-01-21 07:57:00-05:00,ARWR,neutral
98279.0,Arrowhead Pharma Reports Dosing Of First Patient In AROAAT2002 Open Label Phase 2 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease,2019-12-20 07:31:00-05:00,ARWR,neutral
98280.0,Arrowhead Pharmaceuticals shares are trading lower despite earlier announcement the company has filed an application for approval to begin a Phase 1 clinical trial of ARO-HSD.,2019-12-16 10:15:00-05:00,ARWR,positive
98281.0,Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease,2019-12-16 07:33:00-05:00,ARWR,neutral
98282.0,Oppenheimer Initiates Coverage On Arrowhead Pharmaceuticals with Perform Rating,2019-12-13 06:39:00-05:00,ARWR,neutral
98283.0,Arrowhead Pharmaceuticals Files IND For Phase 1b Study Of ARO-HIF2 For Treatment Of Clear Cell Renal Cell Carcinoma,2019-12-11 07:30:00-05:00,ARWR,positive
98284.0,Arrowhead Pharmaceuticals shares are trading higher. Not seeing any news to justify the price action.,2019-12-10 13:46:00-05:00,ARWR,positive
98285.0,38 Stocks Moving In Wednesday's Mid-Day Session,2019-12-04 12:02:00-05:00,ARWR,neutral
98286.0,12 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-12-04 07:34:00-05:00,ARWR,neutral
98287.0,26 Stocks Moving in Wednesday's Pre-Market Session,2019-12-04 07:24:00-05:00,ARWR,neutral
98288.0,Arrowhead Pharmaceuticals shares are trading lower after the company priced its 4 million share common stock offering at $58 per share,2019-12-04 06:11:00-05:00,ARWR,positive
98289.0,Arrowhead Pharmaceuticals Prices 4M Share Offering of Common Stock at $58.00/Share,2019-12-04 06:03:00-05:00,ARWR,positive
98290.0,63 Biggest Movers From Yesterday,2019-12-04 05:15:00-05:00,ARWR,neutral
98291.0,40 Stocks Moving In Tuesday's Mid-Day Session,2019-12-03 12:20:00-05:00,ARWR,neutral
98292.0,Arrowhead Pharmaceuticals shares are trading higher. Not currently seeing any news to justify the price action.,2019-12-03 11:21:00-05:00,ARWR,positive
98293.0,"The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial",2019-12-03 07:59:00-05:00,ARWR,neutral
98294.0,19 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-12-03 07:46:00-05:00,ARWR,neutral
98295.0,22 Stocks Moving in Tuesday's Pre-Market Session,2019-12-03 07:26:00-05:00,ARWR,neutral
98296.0,75 Biggest Movers From Yesterday,2019-12-03 05:48:00-05:00,ARWR,neutral
98297.0,"8 Stocks To Watch For December 3, 2019",2019-12-03 05:13:00-05:00,ARWR,neutral
98298.0,Arrowhead Pharmaceuticals Announces A Proposed Underwritten Offering Of Its Common Stock,2019-12-02 16:06:00-05:00,ARWR,neutral
98299.0,Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.,2019-12-02 11:31:00-05:00,ARWR,negative
98300.0,Arrowhead Pharmaceuticals Option Alert: Jan 17 $75 Calls at the Ask: 1000 @ $5.5 vs 449 OI; Ref=$66.9188,2019-12-02 11:08:00-05:00,ARWR,positive
98301.0,7 Biggest Price Target Changes For Friday,2019-11-29 08:53:00-05:00,ARWR,neutral
98302.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-27 10:14:00-05:00,ARWR,neutral
98303.0,"The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen",2019-11-27 07:26:00-05:00,ARWR,negative
98304.0,60 Biggest Movers From Yesterday,2019-11-27 05:03:00-05:00,ARWR,neutral
98305.0,Cantor Fitzgerald Says Arrowhead Pharmaceuticals May Be Worth $75-$90/Share In Sale,2019-11-26 13:45:00-05:00,ARWR,positive
98306.0,38 Stocks Moving In Tuesday's Mid-Day Session,2019-11-26 12:09:00-05:00,ARWR,neutral
98307.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-26 11:03:00-05:00,ARWR,neutral
98308.0,Arrowhead Pharmaceuticals shares are trading higher after the company reported FY19 EPS and sales results are up from the same quarter last year.,2019-11-26 10:10:00-05:00,ARWR,positive
98309.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,ARWR,positive
98310.0,45 Biggest Movers From Yesterday,2019-11-26 07:05:00-05:00,ARWR,neutral
98311.0,"Arrowhead Pharmaceuticals FY19 EPS $0.69 Up From $(0.65) YoY, Sales $168.796M Up From $16.142M YoY",2019-11-25 16:01:00-05:00,ARWR,neutral
98312.0,33 Stocks Moving In Monday's Mid-Day Session,2019-11-25 12:28:00-05:00,ARWR,neutral
98313.0,Stocks That Hit 52-Week Highs On Monday,2019-11-25 10:19:00-05:00,ARWR,neutral
98314.0,"Benzinga's Top Upgrades, Downgrades For November 25, 2019",2019-11-25 09:34:00-05:00,ARWR,positive
98315.0,36 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-11-25 08:40:00-05:00,ARWR,neutral
98316.0,Arrowhead Pharmaceuticals shares are trading higher after Baird upgraded the company's stock from Neutral to Outperform and raised the price target from $39 to $70.,2019-11-25 07:44:00-05:00,ARWR,positive
98317.0,18 Stocks Moving In Monday's Pre-Market Session,2019-11-25 07:15:00-05:00,ARWR,neutral
98318.0,"Baird Upgrades Arrowhead Pharmaceuticals to Outperform, Raises Price Target to $70",2019-11-25 06:41:00-05:00,ARWR,neutral
98319.0,"The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More",2019-11-24 16:19:00-05:00,ARWR,positive
98320.0,"The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data",2019-11-20 07:25:00-05:00,ARWR,positive
98321.0,Arrowhead Pharmaceuticals shares are trading higher after Cantor Fitzgerald maintained a Neutral rating on the stock and raised the price target from $24 to $50.,2019-11-19 10:23:00-05:00,ARWR,positive
98322.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-19 10:21:00-05:00,ARWR,neutral
98323.0,"Cantor Fitzgerald Maintains Neutral on Arrowhead Pharmaceuticals, Raises Price Target to $50",2019-11-19 07:46:00-05:00,ARWR,neutral
98324.0,30 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-11-15 08:14:00-05:00,ARWR,neutral
98325.0,Stocks That Hit 52-Week Highs On Thursday,2019-11-14 10:09:00-05:00,ARWR,neutral
98326.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,ARWR,positive
98327.0,Arrowhead Pharmaceuticals shares are trading higher after B. Riley FBR maintained a Buy rating on the stock and raised the price target from $46 to $59 per share.,2019-11-13 13:35:00-05:00,ARWR,positive
98328.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-13 10:12:00-05:00,ARWR,neutral
98329.0,"B. Riley FBR Maintains Buy on Arrowhead Pharmaceuticals, Raises Price Target to $59",2019-11-13 09:27:00-05:00,ARWR,neutral
98330.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,ARWR,neutral
98331.0,Arrowhead Pharmaceuticals shares are trading higher. Not currently seeing any company-specific news.,2019-11-12 12:56:00-05:00,ARWR,positive
98332.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-12 10:11:00-05:00,ARWR,neutral
98333.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,ARWR,neutral
98334.0,"Arrowhead Pharma, J&J's Janssen To Present Phase 2 Data For Investigational Hep B Regimens At The Liver Meeting 2019",2019-11-08 08:10:00-05:00,ARWR,neutral
98335.0,Stocks That Hit 52-Week Highs On Monday,2019-11-04 14:43:00-05:00,ARWR,neutral
98336.0,Arrowhead Pharmaceuticals shares are trading lower. Not seeing any news to justify the price action.,2019-11-04 11:22:00-05:00,ARWR,neutral
98337.0,"The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut",2019-10-31 08:08:00-04:00,ARWR,positive
98338.0,"Cramer Gives His Opinion On CyrusOne, CVS And More",2019-10-30 12:39:00-04:00,ARWR,neutral
98339.0,Arrowhead Pharmaceuticals shares are trading lower after Baird downgraded the company's stock from Outperform to Neutral and announced a $39 price target.,2019-10-24 10:28:00-04:00,ARWR,neutral
98340.0,"Benzinga's Top Upgrades, Downgrades For October 24, 2019",2019-10-24 10:03:00-04:00,ARWR,positive
98341.0,"Baird Downgrades Arrowhead Pharmaceuticals to Neutral, Announces $39 Price Target",2019-10-24 06:16:00-04:00,ARWR,neutral
98342.0,"The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data",2019-10-23 07:54:00-04:00,ARWR,negative
98343.0,Arrowhead Pharmaceuticals shares are trading higher after Chardan Capital maintained a Buy rating on the stock and raised the price target from $32 to $45.,2019-10-22 11:20:00-04:00,ARWR,positive
98344.0,"Chardan Capital Maintains Buy on Arrowhead Pharmaceuticals, Raises Price Target to $45",2019-10-22 09:30:00-04:00,ARWR,neutral
98345.0,Stocks That Hit 52-Week Highs On Friday,2019-10-18 10:18:00-04:00,ARWR,neutral
98346.0,Arrowhead Pharmaceuticals shares are trading higher after the company discussed its developement strategy for its emerging pipiline of RNAi at its R&D conference.,2019-10-18 10:15:00-04:00,ARWR,positive
98347.0,32 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-10-18 08:34:00-04:00,ARWR,neutral
98348.0,"The Daily Biotech Pulse: Intuitive Surgical Earnings, Paratek Pulls Out European Application For Antibiotic, Amgen's Evenity In Europe",2019-10-18 07:07:00-04:00,ARWR,neutral
98349.0,Arrowhead Pharmaceuticals shares are trading higher. Not seeing any company-specific news to justify the price action.,2019-10-17 13:37:00-04:00,ARWR,positive
98350.0,"Benzinga's Top Upgrades, Downgrades For October 3, 2019",2019-10-03 10:07:00-04:00,ARWR,positive
98351.0,12 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-10-03 08:11:00-04:00,ARWR,neutral
98352.0,"Baird Initiates Coverage On Arrowhead Pharmaceuticals with Outperform Rating, Announces $39 Price Target",2019-10-03 06:48:00-04:00,ARWR,neutral
98353.0,Shares of Arrowhead Pharmaceuticals are trading higher. Not currently seeing any company-specific news.,2019-09-30 14:03:00-04:00,ARWR,positive
98354.0,22 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-09-16 08:29:00-04:00,ARWR,neutral
98355.0,Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3,2019-09-16 03:54:00-04:00,ARWR,neutral
98356.0,"The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck",2019-09-15 11:18:00-04:00,ARWR,positive
98357.0,Arrowhead Pharmaceuticals shares are trading higher on seemingly no company specific news.,2019-09-11 15:45:00-04:00,ARWR,neutral
98358.0,Arrowhead Pharma shares trading lower as the company presented at Citi's Annual Biotech Conference today.,2019-09-05 14:20:00-04:00,ARWR,neutral
98359.0,Seeing Dip In Arrowhead Pharmaceuticals Shares; Co. Presenting At Citi Biotech Conference,2019-09-05 13:45:00-04:00,ARWR,positive
98360.0,Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients With Chronic Hepatitis B Infection; Arrowhead Earns $25M Milestone Payment In Connection With Trial Initiation,2019-08-28 07:32:00-04:00,ARWR,neutral
98361.0,"The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study",2019-08-22 07:18:00-04:00,ARWR,positive
98362.0,"The Daily Biotech Pulse: FDA Likes Nabriva's Antibiotic, Snubs Sarepta's DMD Drug; Moderna Gets Fast Track Designation For Zika Vaccine",2019-08-20 07:33:00-04:00,ARWR,negative
98363.0,Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.,2019-08-19 12:31:00-04:00,ARWR,positive
98364.0,Stocks That Hit 52-Week Highs On Monday,2019-08-19 10:53:00-04:00,ARWR,neutral
98365.0,33 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-08-19 08:47:00-04:00,ARWR,neutral
98366.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,ARWR,negative
98367.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-06 08:55:00-04:00,ARWR,neutral
98368.0,Arrowhead Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 EPS and sales results.,2019-08-05 16:01:00-04:00,ARWR,neutral
98369.0,"Arrowhead Pharmaceuticals Q3 EPS $0.21 Misses $0.29 Estimate, Sales $46.7M Miss $54.37M Estimate",2019-08-05 16:00:00-04:00,ARWR,negative
98370.0,Arrowhead Pharma shares are trading higher after the company reported it received Orphan Drug Designation for ARO-ANG3.,2019-07-16 16:05:00-04:00,ARWR,positive
98371.0,Arrowhead Pharma Reports Received Orphan Drug Designation For ARO-ANG3,2019-07-16 16:00:00-04:00,ARWR,neutral
98372.0,60 Biggest Movers From Friday,2019-07-01 05:01:00-04:00,ARWR,neutral
98373.0,Arrowhead Pharmaceuticals shares are trading lower after Cantor Fitzgerald downgraded the stock from Overweight to Neutral.,2019-06-28 12:43:00-04:00,ARWR,negative
98374.0,40 Stocks Moving In Friday's Mid-Day Session,2019-06-28 12:19:00-04:00,ARWR,neutral
98375.0,"Benzinga's Top Upgrades, Downgrades For June 28, 2019",2019-06-28 09:24:00-04:00,ARWR,positive
98376.0,Cantor Fitzgerald Downgrades Arrowhead Pharmaceuticals to Neutral,2019-06-28 07:37:00-04:00,ARWR,neutral
98377.0,"The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO",2019-06-28 07:32:00-04:00,ARWR,negative
98378.0,Arrowhead Pharma Reports Received Fast Track Designation For ARO-AAT For Treatment Of Alpha-1 Liver Disease,2019-06-27 07:32:00-04:00,ARWR,neutral
98379.0,Arrowhead Pharmaceuticals Receives FDA Orphan Drug Designation For ARO-APOC3 Fo The Treatment Of Familial Chylomicronemia Syndrome,2019-06-21 07:33:00-04:00,ARWR,neutral
98380.0,"The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut",2019-06-19 07:51:00-04:00,ARWR,positive
98381.0,"The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering",2019-06-06 07:37:00-04:00,ARWR,neutral
98382.0,"The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache",2019-06-05 07:30:00-04:00,ARWR,positive
98383.0,"The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation",2019-05-29 07:38:00-04:00,ARWR,neutral
98384.0,50 Biggest Movers From Friday,2019-05-28 05:01:00-04:00,ARWR,neutral
98385.0,50 Biggest Movers From Yesterday,2019-05-22 05:12:00-04:00,ARWR,neutral
98386.0,36 Stocks Moving In Tuesday's Mid-Day Session,2019-05-21 12:31:00-04:00,ARWR,neutral
98387.0,Arrowhead Pharma shares trading higher following news the stock will join the S&P SmallCap 600 index.,2019-05-21 11:27:00-04:00,ARWR,positive
98388.0,28 Stocks Moving In Tuesday's Pre-Market Session,2019-05-21 08:06:00-04:00,ARWR,neutral
98389.0,"The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails",2019-05-21 07:40:00-04:00,ARWR,negative
98390.0,"S&P Dow Jones Indices Announces Kontoor Brands and Arrowhead Pharmaceuticals Set to Join S&P SmallCap 600; Kontoor To Replace Orion Group, Arrowhead To Replace Navigators",2019-05-20 17:25:00-04:00,ARWR,positive
98391.0,"Shares of many Healthcare companies are trading higher as markets rebound from the recent volatility caused by uncertainty regarding US-China trade talks. Also, lawmakers were not able to pass a bill that would end 'surprise medical bills'.",2019-05-16 15:09:00-04:00,ARWR,positive
98392.0,"Arrowhead Research Q2 EPS $0.24 Beats $0.19 Estimate, Sales $48.148M Beat $42.56M Estimate",2019-05-08 16:20:00-04:00,ARWR,neutral
98393.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,ARWR,negative
98394.0,"Jim Cramer Weighs In On Exxon, Delta Air Lines And More",2019-05-02 07:46:00-04:00,ARWR,neutral
98395.0,Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.,2019-04-30 12:16:00-04:00,ARWR,negative
98396.0,"Arrowhead Pharma Reports Commenced Triple Combo Cohort In Chronic HBV Patients, Earned $25M Milestone Payment From J&J's Janssen",2019-04-24 07:45:00-04:00,ARWR,neutral
98397.0,Shares of several healthcare companies are trading lower on continued weakness over concerns of 'Medicare for all' support within 2020 presidential candidates and the uncertainty over healthcare policy going into the election.,2019-04-18 10:42:00-04:00,ARWR,negative
98398.0,Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.,2019-04-17 10:38:00-04:00,ARWR,positive
98399.0,Arrowhead Pharma Receives FDA Clearance for its Phase 2/3 Study of ARO-AAT for Treatement of Alpah-1 Liver Disease,2019-04-15 07:32:00-04:00,ARWR,neutral
98400.0,Arrowhead Pharmaceuticals Highlights Presentation Of Clinical Data On JNJ-3989 (ARO-HBV) At International Liver Congress,2019-04-12 12:47:00-04:00,ARWR,neutral
98401.0,"Arrowhead Pharma Presented Preclinical Data Showing RNAi Therapy Prevents, Reverses Alpha-1 Liver Disease At Int'l. Liver Congress",2019-04-12 06:07:00-04:00,ARWR,positive
98402.0,Arrowhead Pharmaceuticals Files IND For Pivotal Phase 2/3 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease,2019-03-18 07:32:00-04:00,ARWR,neutral
98403.0,Arrowhead Pharma Begins Dosing for its Phase 1 Study of ARO-APOC3,2019-03-11 07:33:00-04:00,ARWR,neutral
98404.0,66 Biggest Movers From Friday,2019-02-11 04:33:00-05:00,ARWR,neutral
98405.0,48 Stocks Moving In Friday's Mid-Day Session,2019-02-08 12:42:00-05:00,ARWR,neutral
98406.0,"Arrowhead Pharmaceuticals shares are trading higher after the company reported Q1 EPS up 172.22% from last year, and sales up 887.46% from last year.",2019-02-08 10:22:00-05:00,ARWR,positive
98407.0,"Arrowhead Research Q1 EPS $0.13 May Not compare To $0.54 Estimate, Sales $34.66M May Not Compare To $74.76M Estimate",2019-02-07 16:01:00-05:00,ARWR,neutral
98408.0,"The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut",2019-02-07 08:08:00-05:00,ARWR,neutral
98409.0,"The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs",2019-02-03 10:09:00-05:00,ARWR,neutral
98410.0,Arrowhead Pharmaceuticals shares are trading higher after the company announced it began dosing in Phase 1 study of ARO-ANG3.,2019-01-07 11:47:00-05:00,ARWR,positive
98411.0,Arrowhead Pharma Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia,2019-01-07 07:46:00-05:00,ARWR,neutral
98412.0,"Cantor Fitzgerald Maintains Overweight on Arrowhead Pharmaceuticals, Raises Price Target to $165",2018-12-17 09:03:00-05:00,ARWR,negative
98413.0,52 Biggest Movers From Yesterday,2018-12-13 04:54:00-05:00,ARWR,neutral
98414.0,"The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel",2018-12-12 08:07:00-05:00,ARWR,positive
98415.0,"Arrowhead Pharma FY18 EPS $(0.65) vs $(0.47) In FY17, Sales $16.142M vs $31.408M In FY17",2018-12-11 16:01:00-05:00,ARWR,neutral
98416.0,"The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings",2018-12-11 08:22:00-05:00,ARWR,neutral
98417.0,"Earnings Scheduled For December 11, 2018",2018-12-11 04:07:00-05:00,ARWR,neutral
98418.0,"The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings",2018-12-08 10:02:00-05:00,ARWR,neutral
98419.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-11 09:10:00-05:00,ARWR,neutral
98420.0,"Jim Cramer Shares His Thoughts On Amarin, AT&T, McDonald's And More",2018-10-19 06:34:00-04:00,ARWR,positive
98421.0,Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1 Study Of ARO-ANG3,2018-10-15 07:30:00-04:00,ARWR,neutral
98422.0,45 Biggest Movers From Yesterday,2018-10-05 06:12:00-04:00,ARWR,neutral
98423.0,Analysts React To Arrowhead's Janssen Collaboration: Downside In Stock May Be 'Misguided',2018-10-04 13:53:00-04:00,ARWR,negative
98424.0,"UPDATE: FBR B. Riley's Kumar Tells Benzinga Investors Are Likely 'Selling The News', Says Negative Sentiment May Be Misguided",2018-10-04 11:54:00-04:00,ARWR,negative
98425.0,"Arrowhead Pharmaceuticals Shares Down 14.2%; FBR B. Riley's Madhu Kumar Tells Benzinga Investors Are Perceiving HBV Collab. With Janssen As Arrowhead 'Giving Away' Its Lead Asset, Making Co. Less Of An Acquisition Target",2018-10-04 11:54:00-04:00,ARWR,positive
98426.0,Arrowhead Announces $3.7B License Agreement With Janssen For Gene-Silencing Drug,2018-10-04 10:12:00-04:00,ARWR,positive
98427.0,"Arrowhead Pharmaceuticals On Conference Call Says Working On HBV With J&J, Not Going To Create A Competing HBV Product",2018-10-04 08:51:00-04:00,ARWR,negative
98428.0,Arrowhead Pharmaceuticals On Conference Call Says No Longer Dependent On Partnerships To Fund Rest Of Pipeline,2018-10-04 08:45:00-04:00,ARWR,negative
98429.0,"Arrowhead Pharma Shares Resume Trade, Up 24%",2018-10-04 07:51:00-04:00,ARWR,positive
98430.0,Arrowhead Pharma Shares To Resume Trade At 7:50 a.m. EDT,2018-10-04 07:32:00-04:00,ARWR,positive
98431.0,UPDATE: Arrowhead Eligible To Receive Added $3.5B In Potential Milestone Payments,2018-10-04 07:32:00-04:00,ARWR,neutral
98432.0,"UPDATE: Arrowhead Will Receive $250M Upon Closing Of License, Collab Deal With J&J's Janssen",2018-10-04 07:31:00-04:00,ARWR,neutral
98433.0,"Arrowhead Reports $3.7B License, Collaboration Deal With J&J's Janssen",2018-10-04 07:31:00-04:00,ARWR,neutral
98434.0,Arrowhead Pharma Shares Halted News Pending,2018-10-04 07:25:00-04:00,ARWR,positive
98435.0,"Stocks That Made New 52-Week Highs Yesterday, September 6th",2018-09-07 16:47:00-04:00,ARWR,neutral
98436.0,"The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering",2018-09-07 07:55:00-04:00,ARWR,neutral
98437.0,55 Biggest Movers From Yesterday,2018-09-07 05:17:00-04:00,ARWR,neutral
98438.0,Mid-Afternoon Market Update: Crude Oil Down 1.2%; Cloudera Shares Climb On Upbeat Earnings,2018-09-06 14:32:00-04:00,ARWR,negative
98439.0,Arrowhead Pharmaceuticals shares are up 44.8% after the company earlier reported its ARO-HBV was well tolerated in HBV patients; Analysts at B. Riley FBR upgraded the stock form Neutral to Buy.,2018-09-06 12:52:00-04:00,ARWR,positive
98440.0,40 Stocks Moving In Thursday's Mid-Day Session,2018-09-06 12:31:00-04:00,ARWR,neutral
98441.0,Mid-Day Market Update: NASDAQ Down Over 1%; WSI Industries Shares Spike Higher,2018-09-06 12:01:00-04:00,ARWR,positive
98442.0,Mid-Morning Market Update: Markets Mixed; Navistar Profit Tops Estimates,2018-09-06 10:14:00-04:00,ARWR,positive
98443.0,"Benzinga's Top Upgrades, Downgrades For September 6, 2018",2018-09-06 09:06:00-04:00,ARWR,positive
98444.0,B. Riley FBR Upgrades Arrowhead Pharmaceuticals to Buy,2018-09-06 08:46:00-04:00,ARWR,neutral
98445.0,21 Stocks Moving In Thursday's Pre-Market Session,2018-09-06 08:01:00-04:00,ARWR,neutral
98446.0,"Arrowhead Pharmaceuticals Says ARO-HBV Was Generally Well-Tolerated In HBV Patients, Says Up To 4.0 log10 Reduction In HBsAg Was Observed Following 3 Doses Of ARO-HBV",2018-09-06 07:32:00-04:00,ARWR,neutral
98447.0,54 Biggest Movers From Yesterday,2018-09-06 05:13:00-04:00,ARWR,neutral
98448.0,40 Stocks Moving In Wednesday's Mid-Day Session,2018-09-05 12:40:00-04:00,ARWR,neutral
98449.0,26 Stocks Moving In Wednesday's Pre-Market Session,2018-09-05 08:01:00-04:00,ARWR,neutral
98450.0,Arrowhead Pharma Reports Completion Of Dosing In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease,2018-08-31 07:31:00-04:00,ARWR,neutral
98451.0,"Arrowhead Research Q3 EPS $(0.18), Inline, Sales $727.375K Beat $690K Estimate",2018-08-07 17:29:00-04:00,ARWR,neutral
98452.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,ARWR,negative
98453.0,Arrowhead Pharmaceuticals Earns $10M Milestone Payment From Amgen Following Administration Of First Dose Of AMG 890 In A Clinical Study,2018-08-01 07:41:00-04:00,ARWR,neutral
98454.0,50 Biggest Movers From Yesterday,2018-07-31 04:23:00-04:00,ARWR,neutral
98455.0,Arrowhead Pharma Shares Down 12.4%; Some Speculate Amgen Head Of R&D Announcing On Fri. He's Leaving Amgen Could Have Implications For Arrowhead's Research Program For ARO-AMG1,2018-07-30 15:47:00-04:00,ARWR,positive
98456.0,35 Stocks Moving In Monday's Mid-Day Session,2018-07-30 12:59:00-04:00,ARWR,neutral
98457.0,Arrowhead Pharma Shares At Session Lows Down 20.4%; Not Seeing News To Justify Sharp Move Lower; Stock Broke Below Technical Level At $16 Immediately After Mon. Open,2018-07-30 12:34:00-04:00,ARWR,negative
98458.0,"Stocks Which Set New 52-Week High Yesterday, July 24th:",2018-07-25 12:14:00-04:00,ARWR,neutral
98459.0,"Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage",2018-07-10 08:11:00-04:00,ARWR,positive
98460.0,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,2018-07-05 12:25:00-04:00,ARWR,neutral
98461.0,"Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index",2018-07-05 07:43:00-04:00,ARWR,neutral
98462.0,"Benzinga's Daily Biotech Pulse: Titan's Parkinson's Disease Drug Implant Trial, Juniper Pharma Sells Itself At 32% Premium",2018-07-03 07:51:00-04:00,ARWR,neutral
98463.0,"Arrowhead Pharma To Present New Preclinical, Initial Clinical Data On ARO-ATT At National Education Conference",2018-06-29 07:36:00-04:00,ARWR,neutral
98464.0,Arrowhead Pharma Reports EMA's Committee For Orphan Medicinal Products Issued Positive Opinion On Co.'s Application For Orphan Designation Of ARO-AAT For Treatment Of Congenital Alpha-1 Antitrypsin Deficiency,2018-06-27 07:32:00-04:00,ARWR,positive
98465.0,"Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading",2018-06-20 08:36:00-04:00,ARWR,negative
98466.0,"Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares",2018-06-19 08:08:00-04:00,ARWR,positive
98467.0,60 Biggest Movers From Yesterday,2018-06-19 04:02:00-04:00,ARWR,neutral
98468.0,Arrowhead Pharmaceuticals On Monday Closed Up 23.8% After Co. Completed Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease,2018-06-18 17:38:00-04:00,ARWR,neutral
98469.0,Arrowhead Pharma Completes Enrollment in Phase 1 Study of ARO-AAT,2018-06-18 07:31:00-04:00,ARWR,neutral
98470.0,"Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi",2018-06-14 08:11:00-04:00,ARWR,negative
98471.0,"Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time",2018-05-31 08:22:00-04:00,ARWR,positive
98472.0,Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV,2018-05-30 07:51:00-04:00,ARWR,neutral
98473.0,Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV,2018-05-14 07:33:00-04:00,ARWR,neutral
98474.0,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",2018-05-10 09:44:00-04:00,ARWR,neutral
98475.0,54 Biggest Movers From Yesterday,2018-05-10 05:16:00-04:00,ARWR,neutral
98476.0,48 Stocks Moving In Wednesday's Mid-Day Session,2018-05-09 12:56:00-04:00,ARWR,neutral
98477.0,"Benzinga's Top Upgrades, Downgrades For May 9, 2018",2018-05-09 09:13:00-04:00,ARWR,positive
98478.0,"The Market In 5 Minutes: Iran Deal, Google's Virtual Assistant, Walmart-Flipkart",2018-05-09 09:09:00-04:00,ARWR,neutral
98479.0,22 Stocks Moving In Wednesday's Pre-Market Session,2018-05-09 08:10:00-04:00,ARWR,neutral
98480.0,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,2018-05-09 07:25:00-04:00,ARWR,neutral
98481.0,Cantor Fitzgerald Upgrades Arrowhead Pharmaceuticals to Overweight,2018-05-09 06:17:00-04:00,ARWR,negative
98482.0,"Arrowhead Research Q2 EPS $(0.18) Beats $(0.19) Estimate, Sales $650.125K Miss $1.85M Estimate",2018-05-08 17:16:00-04:00,ARWR,negative
98483.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,ARWR,neutral
98484.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,ARWR,neutral
98485.0,30 Stocks Moving In Tuesday's Mid-Day Session,2018-03-27 12:31:00-04:00,ARWR,neutral
98486.0,Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B,2018-03-27 07:34:00-04:00,ARWR,neutral
98487.0,"Jefferies Initiates Coverage On Arrowhead Pharmaceuticals with Buy Rating, Announces $10.00 Price Target",2018-03-27 07:15:00-04:00,ARWR,neutral
98488.0,Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease,2018-03-12 07:32:00-04:00,ARWR,neutral
98489.0,22 Stocks Moving In Tuesday's Pre-Market Session,2018-02-27 07:47:00-05:00,ARWR,neutral
98490.0,38 Biggest Movers From Yesterday,2018-02-27 04:58:00-05:00,ARWR,neutral
98491.0,Arrowhead Pharma Release Confirms Earlier News Co. Received Orphan Drug Designation For ARO-AAT,2018-02-15 13:33:00-05:00,ARWR,neutral
98492.0,Watching Arrowhead Pharma Shares As Traders Circulating FDA Orphan Drug Alert For ADS-001 RNA Interference-Based Liver Targeted Therapeutic,2018-02-15 12:03:00-05:00,ARWR,positive
98493.0,22 Stocks Moving In Thursday's Pre-Market Session,2018-02-15 08:41:00-05:00,ARWR,neutral
98494.0,Arrowhead Pharma Reports Received Regulatory Clearance To Begin Phase 1/2 Study Of ARO-HBV For Treatment Of Hep B,2018-02-15 07:34:00-05:00,ARWR,neutral
98495.0,"Arrowhead Pharma Reports Q1 EPS $(0.18) From $(0.17) YoY, Sales $3.51M From $4.37M YoY",2018-02-09 16:01:00-05:00,ARWR,neutral
98496.0,"Earnings Scheduled For February 9, 2018",2018-02-09 04:09:00-05:00,ARWR,neutral
98497.0,Arrowhead Pharmaceuticals Prices 10M Share Offering At $5.25/Share,2018-01-18 09:02:00-05:00,ARWR,positive
98498.0,26 Stocks Moving In Thursday's Pre-Market Session,2018-01-18 08:08:00-05:00,ARWR,neutral
98499.0,"10 Stocks To Watch For January 18, 2018",2018-01-18 04:43:00-05:00,ARWR,neutral
98500.0,"Arrowhead Pharma Reports Offering Of Common Stock, No Terms Disclosed",2018-01-17 16:03:00-05:00,ARWR,negative
98501.0,38 Biggest Movers From Friday,2018-01-16 05:26:00-05:00,ARWR,neutral
98502.0,33 Stocks Moving In Friday's Mid-Day Session,2018-01-12 12:25:00-05:00,ARWR,neutral
98503.0,"B. Riley Initiates Coverage On Arrowhead Pharmaceuticals with Neutral Rating, Announces $3.00 Price Target",2018-01-05 09:24:00-05:00,ARWR,neutral
98504.0,"Arrowhead Pharma Shares Continuing Higher Thurs. Following 25% Rally On Wed. After Price Broke Above $4 Level; Stock Traded Over $5 Level This Morning, Pulled Back From High; Not Seeing News To Justify Upside",2018-01-04 12:47:00-05:00,ARWR,negative
98505.0,40 Biggest Movers From Yesterday,2018-01-04 05:30:00-05:00,ARWR,neutral
98506.0,"Arrowhead Pharma Shares Close Up 24.7% On No News, But Breakout Above $4 Resistance Level; Stock Up 40+% Since Announcing Filing For Regulatory Clearance Of ARO-AAT, ARO-HBV On Dec. 20, Dec. 22, Respectively",2018-01-03 17:22:00-05:00,ARWR,positive
98507.0,Silence Therapeutics Liquidates Most of Stake in Arrowhead Pharmaceuticals,2017-12-28 04:33:00-05:00,ARWR,neutral
98508.0,Arrowhead Pharma Names William Waddill As Independent Director On Board,2017-12-27 16:00:00-05:00,ARWR,neutral
98509.0,32 Stocks Moving In Tuesday's Pre-Market Session,2017-12-26 08:12:00-05:00,ARWR,neutral
98510.0,44 Biggest Movers From Friday,2017-12-26 05:09:00-05:00,ARWR,neutral
98511.0,36 Stocks Moving In Friday's Mid-Day Session,2017-12-22 12:33:00-05:00,ARWR,neutral
98512.0,Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV,2017-12-22 07:31:00-05:00,ARWR,neutral
98513.0,Arrowhead Pharma Reports Filing Of Regulatory Clearance To Commence Phase 1 Study Of ARO-AAT,2017-12-20 07:30:00-05:00,ARWR,neutral
98514.0,30 Biggest Movers From Yesterday,2017-12-14 05:25:00-05:00,ARWR,neutral
98515.0,32 Stocks Moving In Wednesday's Mid-Day Session,2017-12-13 12:37:00-05:00,ARWR,neutral
98516.0,30 Stocks Moving In Wednesday's Pre-Market Session,2017-12-13 08:15:00-05:00,ARWR,neutral
98517.0,8 Stocks Moving In Tuesday's After-Hours Session,2017-12-12 17:53:00-05:00,ARWR,neutral
98518.0,"Arrowhead Pharma Reports FY17 EPS $(0.47) vs $(1.34) In Same Qtr. Last Year, Sales $31.408M vs $158.3K YoY",2017-12-12 16:00:00-05:00,ARWR,neutral
98519.0,"Earnings Scheduled For December 12, 2017",2017-12-12 04:05:00-05:00,ARWR,neutral
98520.0,Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy,2017-12-06 07:14:00-05:00,ARWR,neutral
98521.0,Seeing Notable Block Trade In Arrowhead Pharmaceuticals; 3.3M Shares At $3.60 Blow Bid Of $3.68,2017-11-29 15:45:00-05:00,ARWR,negative
98522.0,"Piper Jaffray Healthcare Conference 2017 Begins Today, Presenters Include: Civitas Solutions, Insulet, ACADIA Healthcare, Nektar Therapeutics, Quidel, and Arrowhead Pharmaceuticals",2017-11-28 08:57:00-05:00,ARWR,positive
98523.0,"Benzinga's Top Upgrades, Downgrades For November 27, 2017",2017-11-27 09:05:00-05:00,ARWR,positive
98524.0,PiperJaffray Upgrades Arrowhead Pharmaceuticals to Overweight,2017-11-27 07:40:00-05:00,ARWR,negative
98525.0,28 Stocks Moving In Tuesday's Pre-Market Session,2017-10-31 08:09:00-04:00,ARWR,neutral
98526.0,12 Biggest Mid-Day Gainers For Monday,2017-09-18 12:29:00-04:00,ARWR,neutral
98527.0,"Benzinga's Top Upgrades, Downgrades For September 18, 2017",2017-09-18 09:20:00-04:00,ARWR,positive
98528.0,22 Stocks Moving In Monday's Pre-Market Session,2017-09-18 08:07:00-04:00,ARWR,neutral
98529.0,William Blair Upgrades Arrowhead Pharmaceuticals to Outperform,2017-09-18 06:44:00-04:00,ARWR,neutral
98530.0,18 Biggest Mid-Day Gainers For Friday,2017-09-15 12:21:00-04:00,ARWR,neutral
98531.0,"Arrowhead Reports Q3 EPs $(0.07) vs $(0.14) Est., Sales $9.342M May Not Compare To $5.13M Est.",2017-08-03 16:59:00-04:00,ARWR,neutral
98532.0,Mid-Afternoon Market Update: Crude Oil Drops 5%; Alpha and Omega Semi Shares Gain On Earnings Beat,2017-05-04 14:31:00-04:00,ARWR,positive
98533.0,20 Biggest Mid-Day Gainers For Thursday,2017-05-04 12:20:00-04:00,ARWR,neutral
98534.0,Mid-Day Market Update: Crude Oil Down 4%; Insight Enterprises Shares Surge After Strong Q1 Results,2017-05-04 12:04:00-04:00,ARWR,positive
98535.0,Mid-Morning Market Update: Markets Edge Lower; Viacom Beats Q2 Expectations,2017-05-04 10:07:00-04:00,ARWR,negative
98536.0,"Arrowhead Reports Q2 EPS $(0.08) vs $(0.12) Est., Sales $8.986M May Not Compare To $5.51M Est.",2017-05-03 16:37:00-04:00,ARWR,neutral
98537.0,Arrowhead Pharma Adopts Shareholder Rights Agreement,2017-03-23 07:33:00-04:00,ARWR,positive
98538.0,"Exclusive: Dicerna CEO Talks Goals For 2017, Competitors And Prospects Under Trump",2017-02-22 14:36:00-05:00,ARWR,positive
98539.0,"Arrowhead Reports Q1 EPS $(0.17) vs. Est. $(0.20), Rev. $4.3M",2017-02-06 16:00:00-05:00,ARWR,neutral
98540.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-02-01 08:18:00-05:00,ARWR,neutral
98541.0,15 Biggest Mid-Day Gainers For Wednesday,2017-01-11 12:35:00-05:00,ARWR,neutral
98542.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-01-11 08:22:00-05:00,ARWR,neutral
98543.0,15 Stocks Moving In Monday's Pre-Market Session,2017-01-09 08:22:00-05:00,ARWR,neutral
98544.0,UPDATE: Silence Therapeutics Announces Acquisition of 8.4% Stake in Arrowhead; Says  'Recent Technological Advancements in RNA Therapeutics have been Underestimated and Undervalued',2017-01-09 04:15:00-05:00,ARWR,negative
98545.0,Arrowhead Acknowledges 8.4% Stake by Silence Therapeutics,2017-01-09 04:11:00-05:00,ARWR,neutral
98546.0,Arrowhead Pharmaceuticals Pops to High of $1.66 on Volume,2016-12-29 15:59:00-05:00,ARWR,neutral
98547.0,Arrowhead Reports FY16 EPS $(1.34) vs. Prior Year Quarter $(1.60),2016-12-14 16:00:00-05:00,ARWR,neutral
98548.0,"Earnings Scheduled For December 14, 2016",2016-12-14 05:33:00-05:00,ARWR,neutral
98549.0,"8-K from Arrowhead Pharma Shows Co. Notified Chief Scientific Officer, David Lewis, to Terminate",2016-12-01 16:49:00-05:00,ARWR,neutral
98550.0,Mid-Afternoon Market Update: Arrowhead Pharma Tumbles Following EX-1 RNAi Program Discontinuations; Arbutus Biopharma Shares Surge,2016-11-30 14:22:00-05:00,ARWR,positive
98551.0,18 Biggest Mid-Day Losers For Wednesday,2016-11-30 12:57:00-05:00,ARWR,negative
98552.0,Mid-Day Market Update: Crude Oil Up Over 8%; American Eagle Shares Plummet On Weak Guidance,2016-11-30 12:21:00-05:00,ARWR,negative
98553.0,Stocks Hitting 52-Week Lows,2016-11-30 10:24:00-05:00,ARWR,negative
98554.0,Mid-Morning Market Update: Markets Mostly Higher; GoPro To Reduce 15% Of Workforce,2016-11-30 10:05:00-05:00,ARWR,neutral
98555.0,10 Biggest Price Target Changes For Wednesday,2016-11-30 09:37:00-05:00,ARWR,neutral
98556.0,Alnylam Is Now The Leader In The Clinical HBV RNAi Therapy Space,2016-11-30 09:32:00-05:00,ARWR,neutral
98557.0,"The Market In 5 Minutes: OPEC, Earnings And Trump's Cabinet",2016-11-30 09:05:00-05:00,ARWR,neutral
98558.0,Benzinga's Top Downgrades,2016-11-30 08:59:00-05:00,ARWR,positive
98559.0,William Blair Downgrades Arrowhead Pharmaceuticals to Market Perform,2016-11-30 08:46:00-05:00,ARWR,neutral
98560.0,25 Stocks Moving In Wednesday's Pre-Market Session,2016-11-30 08:28:00-05:00,ARWR,neutral
98561.0,Arrowhead Pharma Downgraded Following EX-1 RNAi Program Discontinuations,2016-11-30 07:28:00-05:00,ARWR,neutral
98562.0,PiperJaffray Downgrades Arrowhead Pharmaceuticals to Neutral,2016-11-30 07:24:00-05:00,ARWR,neutral
98563.0,Cantor Fitzgerald Downgrades Arrowhead Pharmaceuticals to Hold,2016-11-30 07:24:00-05:00,ARWR,neutral
98564.0,Chardan Capital Raises Price Target on Alnylam Pharma from $73 to $89 'In light of the removal of the Arrowhead programs from development'; Maintains Buy,2016-11-30 06:36:00-05:00,ARWR,neutral
98565.0,Chardan Capital Downgrades Arrowhead Pharmaceuticals to Neutral,2016-11-30 06:29:00-05:00,ARWR,neutral
98566.0,"Arowhead Pharma Shares Resume Trade, Now Down Nearly 70%",2016-11-29 16:31:00-05:00,ARWR,positive
98567.0,UPDATE: Arrowhead Pharma Says Will Reduce Workforce by ~30%,2016-11-29 16:13:00-05:00,ARWR,neutral
98568.0,Arrowhead Pharma Shares to Resume Trade at 4:30 p.m. EDT,2016-11-29 16:11:00-05:00,ARWR,positive
98569.0,"UPDATE: Arrowhead Cites Two Primary Reason for Discontinuation: 'became apparent that there would be substantial delays in all clinical programs that utilize EX1,' Co.'s ' substantial advances in RNA chemistry and targeting'",2016-11-29 16:04:00-05:00,ARWR,positive
98570.0,"Arrowhead To Discontinue Development Of Clinical State Drug Candidates ARC-520, ARC-521, and ARC-AAT",2016-11-29 16:03:00-05:00,ARWR,neutral
98571.0,Arrowhead Shares Halted News Pending,2016-11-29 16:00:00-05:00,ARWR,positive
98572.0,Deaths Observed In Arrowhead Pharma's Clinical Study Don't Change Cantor's Buy Rating,2016-11-09 14:45:00-05:00,ARWR,neutral
98573.0,20 Biggest Mid-Day Losers For Wednesday,2016-11-09 13:10:00-05:00,ARWR,negative
98574.0,A Couple Of News Dumps You May Have Missed On Tuesday Night,2016-11-09 12:49:00-05:00,ARWR,negative
98575.0,"Cantor Fitzgerald Analyst Reiterates Buy, $15 Target on Arrowhead Pharma Following Clinical Hold News, 30% Decline in Stock Today",2016-11-09 10:46:00-05:00,ARWR,neutral
98576.0,25 Stocks Moving In Wednesday's Pre-Market Session,2016-11-09 08:28:00-05:00,ARWR,neutral
98577.0,Arrowhead Pharmaceuticals Says Notified Verbally By FDA of Decision to Place Clinical Hold On Heparc-2004,2016-11-08 20:07:00-05:00,ARWR,neutral
98578.0,Arrowhead Pharmaceuticals Files For $200M Mixed Shelf Offering,2016-10-28 17:08:00-04:00,ARWR,neutral
98579.0,"Selling Shareholder Amgen Selling 3M Shares Of Arrowhead Pharmaceuticals, Arrowhead Will Not Receive Any Proceeds From The Sale",2016-10-28 16:46:00-04:00,ARWR,positive
98580.0,15 Stocks Which Plummeted Three Days On Increasing Volume,2016-10-27 07:25:00-04:00,ARWR,neutral
98581.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-10-06 08:43:00-04:00,ARWR,neutral
98582.0,16 Stocks Moving In Friday's Pre-Market Session,2016-09-30 08:33:00-04:00,ARWR,neutral
98583.0,15 Biggest Mid-Day Gainers For Thursday,2016-09-29 12:54:00-04:00,ARWR,neutral
98584.0,Arrowhead's Landmark Deal With Amgen Sends Shares Shooting Higher,2016-09-29 12:25:00-04:00,ARWR,positive
98585.0,"Cantor Fitzgerald Analyst Reiterates Buy, $15 Target on Arrowhead Pharma; Calls Deal with Amgen 'Landmark'",2016-09-29 10:47:00-04:00,ARWR,neutral
98586.0,Mid-Morning Market Update: Markets Edge Lower; PepsiCo Beats Q3 Expectations,2016-09-29 10:06:00-04:00,ARWR,negative
98587.0,15 Stocks Moving In Thursday's Pre-Market Session,2016-09-29 08:20:00-04:00,ARWR,neutral
98588.0,Arrowhead Pharma Shares to Resume Trade at 8 a.m. EDT,2016-09-29 07:36:00-04:00,ARWR,positive
98589.0,UPDATE: Amgen Will Receive Global Exclusive License to Arrowhead's RNAi ARC-LPA Program,2016-09-29 07:33:00-04:00,ARWR,positive
98590.0,"UPDATE: Arrowhead Will Receive $56.5M in Upfront Payments, Up to Added $617M in Potential Milestones",2016-09-29 07:32:00-04:00,ARWR,neutral
98591.0,"Amgen, Arrowhead Pharma Report Two Cardiovacular Collaborations",2016-09-29 07:32:00-04:00,ARWR,neutral
98592.0,Arrowhead Pharma Shares Halted News Pending,2016-09-29 07:26:00-04:00,ARWR,positive
98593.0,Arrowhead Pharma Reports Dosing of First Patient with Hep B in Multiple Ascending Dose Portion of Phase 1/2 Study of ARC-521,2016-09-07 07:31:00-04:00,ARWR,neutral
98594.0,Arrowhead Pharmaceuticals Begins Phase 2 Study of ARC-AAT,2016-09-06 07:30:00-04:00,ARWR,neutral
98595.0,15 Biggest Mid-Day Gainers For Thursday,2016-08-18 13:49:00-04:00,ARWR,neutral
98596.0,Benzinga's Top Initiations,2016-08-18 09:32:00-04:00,ARWR,positive
98597.0,20 Stocks Moving In Thursday's Pre-Market Session,2016-08-18 08:40:00-04:00,ARWR,neutral
98598.0,Cantor Fitzgerald Initiates Coverage on Arrowhead Pharmaceuticals at Buy,2016-08-18 07:45:00-04:00,ARWR,neutral
98599.0,Option Alert: ARWR Sep16 7.0 Calls: 1000 @  ASK  $0.30: 2004 traded vs 833 OI: $6.25 Ref,2016-08-17 15:26:00-04:00,ARWR,positive
98600.0,Watch These 7 Huge Call Purchases In Wednesday Trade,2016-08-10 04:02:00-04:00,ARWR,positive
98601.0,"After-Hours Losers Aug. 9, 2016: SPWR Down 29%, MYGN 23%, TDW 18.5%, YUME 10.2%, ARWR 9.2%, LSCC 8.6%, LOAN 8.5%, CYBR 6%",2016-08-09 19:17:00-04:00,ARWR,negative
98602.0,"Arrowhead Pharmaceuticals Reports Q3 EPS $(0.32) vs. Est. $(0.37), Rev. $39.58k  vs. Est. $60K",2016-08-09 16:26:00-04:00,ARWR,neutral
98603.0,There Have Been 20 Secondary Offerings Over The Last 2 Days,2016-08-09 14:05:00-04:00,ARWR,neutral
98604.0,Option Alert: ARWR Sep16 6.0 Calls Sweep: 3209 @  ASK  $0.50: 3215 traded vs 497 OI:  Earnings today After Close  $5.63 Ref,2016-08-09 10:13:00-04:00,ARWR,positive
98605.0,Arrowhead Pharma Prices Offering of ~7.63M Shares at $5.90/Share for Gross Proceeds $45M,2016-08-09 09:05:00-04:00,ARWR,negative
98606.0,Arbutus Biopharma Taken Off Of Chardan's Sell List,2016-06-16 09:29:00-04:00,ARWR,neutral
98607.0,"Arrowhead Pharma Reports Initiation of Phase 1/2 Single, Multiple Dose Study of Hep B Candidate ARC-521",2016-06-09 07:31:00-04:00,ARWR,neutral
98608.0,5 Reasons Arrowhead Pharma Is A Hepatitis B Leader,2016-05-19 12:38:00-04:00,ARWR,neutral
98609.0,The Market In 5 Minutes: The Oscars Of Fintech Is Coming,2016-05-19 09:48:00-04:00,ARWR,neutral
98610.0,"Chardan Capital Initiates Coverage on Arrowhead Pharmaceuticals at Buy, Announces $12.00 PT",2016-05-19 06:08:00-04:00,ARWR,neutral
98611.0,"Arrowhead Reports Q2 EPS $(0.35) vs. Est. $(0.37), Rev. $43K vs. Est. $70K",2016-05-10 16:14:00-04:00,ARWR,neutral
98612.0,"Arrowhead Says ARC-LPA Achieved 98% Knockdown, Long Duration of Effect After Subcutaneous Admin",2016-05-06 12:00:00-04:00,ARWR,neutral
98613.0,Arrowhead Pharmaceuticals Presents Preclinical Data on Renal Cell Carcinoma Program at AACR 2016,2016-04-18 14:00:00-04:00,ARWR,neutral
98614.0,10 Stocks Moving In Wednesday's Pre-Market Session,2016-04-13 08:18:00-04:00,ARWR,neutral
98615.0,"Arrowhead Announces ARC-520 Presentations To Be Made At ILC 2016, Data Found In Body",2016-04-13 07:34:00-04:00,ARWR,neutral
98616.0,Arrowhead Research Changes Name to Arrowhead Pharmaceuticals,2016-04-06 16:01:00-04:00,ARWR,neutral
98617.0,"Arrowhead Reports Q1 EPS ($0.32) vs. Est. ($0.41), Rev. $43.75 vs. Est. $130K",2016-02-09 16:02:00-05:00,ARWR,neutral
98618.0,Arrowhead Research Falls to Low of $4.25 on Volume,2016-01-19 11:13:00-05:00,ARWR,negative
98619.0,Arrowhead ARC-AAT Granted EMA Orphan Drug Designation,2016-01-19 07:30:00-05:00,ARWR,positive
98620.0,"Wayfair Launches Canadian Website, Wayfair.ca",2016-01-07 07:37:00-05:00,ARWR,neutral
98621.0,Arrowhead Initiates Dosing For Phase 2b MONARCH Combo Study Of ARC-520 With Chronic HBV Infected Patients,2016-01-07 07:37:00-05:00,ARWR,negative
98622.0,"Arrowhead Reports FY15 EPS $(1.60), Sales $382K",2015-12-14 16:05:00-05:00,ARWR,neutral
98623.0,Shares Of Arrowhead Up 12% On The Day With Positive Data On HBV Immune Reactivation In 7 Of 9 Immune Reactivation,2015-12-07 10:14:00-05:00,ARWR,positive
98624.0,Mid-Day Market Update: Breitburn Energy Partners Drops Following News of Distribution Suspension; Mattress Firm Shares Surge,2015-12-01 12:03:00-05:00,ARWR,positive
98625.0,Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA,2015-11-16 11:02:00-05:00,ARWR,neutral
98626.0,US Stock Futures Edge Higher Ahead Of Empire State Manufacturing Index,2015-11-16 07:07:00-05:00,ARWR,neutral
98627.0,Arrowhead Presents Positive Data on ARC-520 in Hepatitis B Infected Chimpanzees at AASLD Liver Meeting 2015,2015-11-15 18:43:00-05:00,ARWR,positive
98628.0,Benzinga's Top #PreMarket Gainers,2015-10-13 08:17:00-04:00,ARWR,positive
98629.0,10 Stocks Moving In Monday's After-Hours Session,2015-09-28 16:47:00-04:00,ARWR,neutral
98630.0,"'We're Confident Arrowhead's ARC-520 Is Active Drug For HBV,' Piper Jaffray Says",2015-09-25 12:04:00-04:00,ARWR,positive
98631.0,Morning Market Gainers,2015-09-25 09:44:00-04:00,ARWR,neutral
98632.0,Benzinga's Top #PreMarket Gainers,2015-09-25 08:12:00-04:00,ARWR,positive
98633.0,Mid-Morning Market Update: Markets Tumble; Accenture Tops Q4 Estimates,2015-09-24 10:33:00-04:00,ARWR,positive
98634.0,Morning Market Gainers,2015-09-24 09:41:00-04:00,ARWR,neutral
98635.0,Benzinga's Top #PreMarket Gainers,2015-09-24 08:08:00-04:00,ARWR,positive
98636.0,Arrowhead Research +25% Premarket Following Announcement of Results of ARC-520 Hep B Study,2015-09-24 07:55:00-04:00,ARWR,neutral
98637.0,Arrowhead Research Announces Peak Reduction in HBsAg of Up to 99% Following Single Dose of ARC-520 for Naive Cohort,2015-09-24 07:34:00-04:00,ARWR,negative
98638.0,Morning Market Gainers,2015-09-11 09:48:00-04:00,ARWR,neutral
98639.0,Arrowhead +10% Premarket as Co Nominates ARC-HIF2 as First RNAi Therapeutic Candidate Using Extrahepatic DPC Delivery System,2015-09-11 08:39:00-04:00,ARWR,neutral
98640.0,Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC Delivery System,2015-09-11 07:31:00-04:00,ARWR,neutral
98641.0,4 Biotechs Piper Jaffray Is Buying On The Pullback,2015-08-26 15:27:00-04:00,ARWR,neutral
98642.0,"Arrowhead Announces Recieved Regulatory Clearance for ARC-AAT Phase 1 in UK, New Zealand",2015-07-08 07:30:00-04:00,ARWR,neutral
98643.0,Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency,2015-07-02 07:33:00-04:00,ARWR,neutral
98644.0,Arrowhead Receives Regulatory Clearance to Begin Additional Phase 2b Studies of Hepatitis B Candidate ARC-520,2015-06-17 07:30:00-04:00,ARWR,neutral
98645.0,Arrowhead Gets Orphan Drug Designation for ARC-AAT,2015-06-10 12:28:00-04:00,ARWR,neutral
98646.0,"Arrowhead Research Reports Q2 Loss $0.51 Vs Est Loss $0.34, Sales $43.750K Vs Est $110.0K",2015-05-11 16:38:00-04:00,ARWR,negative
98647.0,Arrowhead Presents Data on Potential RNAi Candidate Targeting Factor 12 Mediated Angioedemic and Thromboembolic Diseases,2015-05-06 15:19:00-04:00,ARWR,neutral
98648.0,Arrowhead Finishes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT,2015-05-05 07:30:00-04:00,ARWR,positive
98649.0,Analyst Wants Proof On Arrowhead Research's Hepatitis B Drug,2015-04-14 15:38:00-04:00,ARWR,neutral
98650.0,Morning Market Losers,2015-04-14 09:52:00-04:00,ARWR,negative
98651.0,Benzinga's Top #PreMarket Losers,2015-04-14 08:30:00-04:00,ARWR,negative
98652.0,Jefferies Downgrades Arrowhead Research to Hold,2015-04-14 08:13:00-04:00,ARWR,neutral
98653.0,Morning Market Gainers,2015-04-13 09:41:00-04:00,ARWR,neutral
98654.0,Benzinga's Top #PreMarket Gainers,2015-04-13 08:12:00-04:00,ARWR,positive
98655.0,Arrowhead Research Announces Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520,2015-04-13 07:31:00-04:00,ARWR,positive
98656.0,Option Alert: Arrowhead Research Apr $8 Call; 5149 Contract Trade above Ask @$0.29; Now $7.38,2015-04-01 15:46:00-04:00,ARWR,positive
98657.0,Arrowhead Research Soars After Acquiring Novartis' RNAi Portfolio,2015-03-05 12:54:00-05:00,ARWR,neutral
98658.0,Morning Market Gainers,2015-03-05 09:41:00-05:00,ARWR,neutral
98659.0,Benzinga's Top #PreMarket Gainers,2015-03-05 08:13:00-05:00,ARWR,positive
98660.0,The News That Should Move Arrowhead Research Today,2015-02-10 07:09:00-05:00,ARWR,neutral
98661.0,Arrowhead Research Reports Q1 Loss of $0.41/Share vs Loss of $0.34/Share Est.,2015-02-09 16:15:00-05:00,ARWR,negative
98662.0,Arrowhead Research Shares Seeing Significant Short Interest,2015-02-02 11:46:00-05:00,ARWR,positive
98663.0,"Deutsche Bank Downgrades Arrowhead, Says 2015 Is The 'Show-Me Year'",2015-01-22 09:22:00-05:00,ARWR,neutral
98664.0,"Deutsche Bank Downgrades Arrowhead Research to Hold, Lowers PT to $7.00",2015-01-22 06:52:00-05:00,ARWR,negative
98665.0,Mid-Day Market Update: Foundation Medicine Shares Jump Following Deal With Roche; Crude Oil Slides Over 4%,2015-01-12 12:55:00-05:00,ARWR,negative
98666.0,Mid-Morning Market Update: Markets Tumble; Shire To Acquire NPS Pharmaceuticals For $5.2 Billion,2015-01-12 11:37:00-05:00,ARWR,neutral
98667.0,Morning Market Losers,2015-01-12 09:54:00-05:00,ARWR,negative
98668.0,Merger Monday Moving Stocks Monday Morning,2015-01-12 09:48:00-05:00,ARWR,neutral
98669.0,Arrowhead Research Tumbles 20% Following FDA News,2015-01-12 09:13:00-05:00,ARWR,neutral
98670.0,Benzinga's Top #PreMarket Losers,2015-01-12 08:15:00-05:00,ARWR,negative
98671.0,Arrowhead Research Says FDA Informed Co in Preliminary Call of Partial Clinical Hold Under Which Co Cleared to Begin Modified Study of ARC-520,2015-01-12 07:04:00-05:00,ARWR,positive
98672.0,Benzinga's Top #PreMarket Gainers,2015-01-02 08:38:00-05:00,ARWR,positive
98673.0,Biotech Stocks Make Big Moves In Final Days Of 2014,2014-12-31 09:41:00-05:00,ARWR,neutral
98674.0,"Option Alert: Arrowhead Research Jan $10 Call: 1,283 Contracts Traded vs 1 OI; Currently $8.37",2014-12-30 12:59:00-05:00,ARWR,positive
98675.0,Arrowhead Reports Filing of IND for RNAi Therapeutic ARC-520 for Commencement of Phase 2b Multiple-Dose Studies in Chronic Hep B Patients,2014-12-15 07:33:00-05:00,ARWR,neutral
98676.0,8-K from Arrowhead Shows FY14 Loss of $1.25/Share vs Loss of $1.05/Share Est.,2014-11-25 15:59:00-05:00,ARWR,negative
98677.0,Arrowhead Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi Therapeutic ARC-AAT,2014-11-18 07:30:00-05:00,ARWR,neutral
98678.0,Shares of Arrowhead Resources Move Higher on Report CEO to be on CNBC,2014-11-10 12:04:00-05:00,ARWR,positive
98679.0,"Arrowhead Offers Data on ARC-520, ARC-AAT at AASLD The Liver Meeting",2014-11-10 09:18:00-05:00,ARWR,neutral
98680.0,13G Filing from QVT Financial on Arrowhead Research Shows Raised Stake from 3.44% as of Jun. 30 to 7.62%,2014-10-14 14:51:00-04:00,ARWR,neutral
98681.0,The 3 Most Volatile Biotech Stocks,2014-10-14 12:42:00-04:00,ARWR,neutral
98682.0,Arrowhead Issues Open Letter to Shareholders ,2014-10-09 08:32:00-04:00,ARWR,neutral
98683.0,"RBC Capital Downgrades Arrowhead Research Corporation to Sector Perform, Lowers PT to $9.00",2014-10-08 17:36:00-04:00,ARWR,negative
98684.0,Arrowhead Research Corp Hammered On Drug News; Deutsche Bank Lowers Price Target,2014-10-08 14:32:00-04:00,ARWR,negative
98685.0,"Midday Losers From October 8 - Arrowhead Research Corp, A10 Networks Inc. And More",2014-10-08 13:49:00-04:00,ARWR,negative
98686.0,"Deutsche Bank on Arrowhead: 'We see higher risk but do not think program is dead,' Price Target Slashed from $45 to $20",2014-10-08 13:16:00-04:00,ARWR,negative
98687.0,Hearing Deutsche Bank Defending Arrowhead Research,2014-10-08 13:13:00-04:00,ARWR,neutral
98688.0,Hearing Jefferies Defends Arrowhead Research,2014-10-08 11:45:00-04:00,ARWR,neutral
98689.0,Arrowhead Research Corp Down Big On Disappointing Hepatitis B Drug Data,2014-10-08 11:41:00-04:00,ARWR,negative
98690.0,"Shares of Arrowhead Research Halted on Fourth Circuit Breaker, Now Down 42%",2014-10-08 10:59:00-04:00,ARWR,positive
98691.0,"Arrowhead Research Shares Resume Trade, Now Down ~45.5%",2014-10-08 10:54:00-04:00,ARWR,positive
98692.0,"Arrowhead Research Shares Halted on Third Circuit Breaker, Now Down ~48.7%",2014-10-08 10:49:00-04:00,ARWR,positive
98693.0,"Shares of Arrowhead Research Resume, Now Down ~45%",2014-10-08 10:48:00-04:00,ARWR,positive
98694.0,"Shares of Arrowhead Research Halted on Second Circuit Breaker, Now Down ~38%",2014-10-08 10:42:00-04:00,ARWR,positive
98695.0,"Adam Feuerstein ‏@adamfeuerstein Tweet: In case you're wondering, $ARWR selling off bc ARC-520 HepB data in #AASLD14 abstract just released are disappointing.  Details",2014-10-08 10:30:00-04:00,ARWR,negative
98696.0,Arrowhead Research Halted ,2014-10-08 10:28:00-04:00,ARWR,neutral
98697.0,Arrowhead to Present ARC-520 Phase 2a Data in Late-Breaking Session at AASLD Liver Meeting 2014 ,2014-10-08 10:00:00-04:00,ARWR,neutral
98698.0,Morning Market Losers ,2014-10-08 09:48:00-04:00,ARWR,negative
98699.0,Benzinga's Top #PreMarket Losers,2014-10-08 08:09:00-04:00,ARWR,negative
98700.0,Top 5 Biotech Stocks Over The Past Year,2014-10-06 14:28:00-04:00,ARWR,positive
98701.0,"UPDATE: Arrowhead Research Spokesperson Says Spike in Share Price Most Likely Due to Submission of Late Breaking Abstract for AASLD Meeting, But that Was Already Known",2014-09-22 14:57:00-04:00,ARWR,positive
98702.0,UPDATE: Hearing Move in Arrowhead Research May be Attributed to Positive News Regarding Hep B Drug,2014-09-22 14:24:00-04:00,ARWR,positive
98703.0,Arrowhead Research Spikes Higher,2014-09-22 14:20:00-04:00,ARWR,neutral
98704.0,Arrowhead Research Corp Heads Higher After Breakout,2014-09-04 14:51:00-04:00,ARWR,neutral
98705.0,Arrowhead Research Corp Shares Push Over Resistance Level As Momentum Continues,2014-09-03 12:54:00-04:00,ARWR,positive
98706.0,"Winners & Losers From Tuesday, August 26",2014-08-26 16:02:00-04:00,ARWR,negative
98707.0,"Deutsche Bank Sees Achillion, Arrowhead As Potential Takeover Targets",2014-08-26 13:37:00-04:00,ARWR,neutral
98708.0,"Arrowhead Research Corporation Reports Q2 EPS of $(0.22), Inline",2014-08-12 16:02:00-04:00,ARWR,neutral
98709.0,Morning Market Movers ,2014-07-29 09:42:00-04:00,ARWR,neutral
98710.0,Benzinga's Top #PreMarket Gainers,2014-07-29 08:13:00-04:00,ARWR,positive
98711.0,Arrowhead Research Up Over 6% Following CNBC Comments,2014-07-09 11:51:00-04:00,ARWR,neutral
98712.0,Arrowhead Research Spikes Higher on Positive CNBC Comments,2014-07-08 17:50:00-04:00,ARWR,positive
98713.0,4 Biotech Stocks With Big Money Coming In,2014-06-30 15:50:00-04:00,ARWR,neutral
98714.0,Benzinga's Top #PreMarket Losers,2014-06-19 08:13:00-04:00,ARWR,negative
98715.0,"Arrowhead Offers Statement on IP for ARC-520, Does Not Expecting ARC-520 Commercialization Infringing Patents",2014-06-13 17:45:00-04:00,ARWR,neutral
98716.0,"Option Alert: Arrowhead Research Jun $11 Call; 2,064 Contract Trade Between Bid and Ask vs 627 OI; Currently $11.57",2014-06-13 11:15:00-04:00,ARWR,positive
98717.0,Mid-Afternoon Market Update: S&P Looks To Close At All-Time High As Analogic Takes A Hit On Preliminary Results,2014-05-27 15:52:00-04:00,ARWR,neutral
98718.0,Mid-Afternoon Market Update: Markets Trade Up as Bank of America Shares Remain Down,2014-04-16 15:40:00-04:00,ARWR,positive
98719.0,Mid-Day Market Update: Yahoo Jumps On Upbeat Results; ASML Shares Decline,2014-04-16 12:38:00-04:00,ARWR,positive
98720.0,Mid-Afternoon Market Update: Markets Trade in Highly Volatile Session as Talk of a Pull-Back is Widespread,2014-04-15 15:59:00-04:00,ARWR,neutral
98721.0,Amended 13G Filing from Point72 Asset Mgmt on Arrowhead Research Shows 7.1% Stake,2014-04-09 16:34:00-04:00,ARWR,positive
98722.0,Deutsche Bank Remains Positive on Arrowhead Research Despite Weakness,2014-03-25 08:03:00-04:00,ARWR,positive
98723.0,"Deutsche Bank Defends Arrowhead Amid ~16% Decline, Reiterates Buy",2014-03-24 18:10:00-04:00,ARWR,neutral
98724.0,Arrowhead Begins Dosing in Phase 2a Trial of RNAi Therapeutic ARC-520 in Chronic Hepatitis B Patients ,2014-03-24 07:39:00-04:00,ARWR,neutral
98725.0,"UPDATE: Soaring 19%, Deutsche Bank Initiates Coverage on Arrowhead Research",2014-03-05 10:39:00-05:00,ARWR,neutral
98726.0,UPDATE: Deutsche Bank Initiates Coverage on Arrowhead Research on Good Potential,2014-03-05 10:27:00-05:00,ARWR,positive
98727.0,Benzinga's Volume Movers,2014-03-05 10:24:00-05:00,ARWR,neutral
98728.0,Mid-Morning Market Update: Markets Mostly Flat; Brown-Forman Posts Higher Profit,2014-03-05 10:22:00-05:00,ARWR,positive
98729.0,"Morning Movers for Mar. 5, 2014: FCEL, ARWR, SWHC, CPST Moving Higher",2014-03-05 09:52:00-05:00,ARWR,neutral
98730.0,"UPDATE: RBC Capital Sees Arrowhead Research Potentially Attractive M&A, Partnering Interest from Bristol, Merck, Novartis",2014-03-05 08:45:00-05:00,ARWR,positive
98731.0,Benzinga's Top #PreMarket Gainers,2014-03-05 08:08:00-05:00,ARWR,positive
98732.0,Benzinga's Top Initiations,2014-03-05 07:59:00-05:00,ARWR,positive
98733.0,"Deutsche Bank Initiates Coverage on Arrowhead Research Corporation at Buy, Announces $45.00 PT",2014-03-05 07:26:00-05:00,ARWR,neutral
98734.0,"After-Hours Movers: BV, SWHC, AVAV, CTIC Moving Higher, HCI, BOBE, CHEF, THOR Lower",2014-03-04 17:24:00-05:00,ARWR,negative
98735.0,"RBC Capital Initiates Coverage on Arrowhead Research Corporation at Outperform, Announces $35.00 PT",2014-03-04 17:07:00-05:00,ARWR,neutral
98736.0,Benzinga's Top Initiations,2014-03-03 08:17:00-05:00,ARWR,positive
98737.0,"Barclays Initiates Coverage on Arrowhead Research Corporation at Overweight, Announces $32.00 PT",2014-03-03 07:56:00-05:00,ARWR,negative
98738.0,Arrowhead Receives Regulatory Approval to Begin Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520,2014-03-03 07:32:00-05:00,ARWR,positive
98739.0,UPDATE: Arrowhead Announces Pricing of Underwritten 5.5M Share Offering of Common Stock at $18.95 per Share,2014-02-19 09:05:00-05:00,ARWR,positive
98740.0,Arrowhead Prices 5.5M Shares at $18.95/Share,2014-02-19 09:05:00-05:00,ARWR,positive
98741.0,Arrowhead Announces Proposed Underwritten Offering of Common Stock; Size Not Stated,2014-02-18 16:14:00-05:00,ARWR,neutral
98742.0,This Week's Sector Gainers And Losers,2014-02-13 11:38:00-05:00,ARWR,negative
98743.0,"ETF Outlook For Thursday, February 13, 2014 (XSD, VNM, PXN, COPX)",2014-02-13 07:37:00-05:00,ARWR,neutral
98744.0,Arrowhead Research Corporation Reports Q1 EPS of $(0.28) vs $(0.20) Est,2014-02-04 16:15:00-05:00,ARWR,neutral
98745.0,"Jefferies Initiates Coverage on Arrowhead Research Corporation at Buy, Announces $15.00 PT",2013-12-18 06:44:00-05:00,ARWR,neutral
98746.0,"Earnings Scheduled For December 18, 2013",2013-12-18 04:34:00-05:00,ARWR,neutral
98747.0,Arrowhead Issues Phase 1 Data on ARC-520 at HepDART '13,2013-12-09 16:04:00-05:00,ARWR,neutral
98748.0,Arrowhead Pharma Submits Application to Begin Phase 2A Trial of ARC-520,2013-11-25 07:32:00-05:00,ARWR,neutral
98749.0,Benzinga's Top Initiations,2013-10-21 08:02:00-04:00,ARWR,positive
98750.0,"Piper Jaffray Initiates Coverage on Arrowhead Research Corporation at Overweight, Announces $12.00 PT",2013-10-21 06:52:00-04:00,ARWR,negative
98751.0,Arrowhead Priced 3.07M Shares at $5.86/Share,2013-10-14 07:45:00-04:00,ARWR,positive
98752.0,Arrowhead Prices Offering at $5.86/Share for Net Proceeds of $60M,2013-10-08 08:57:00-04:00,ARWR,neutral
98753.0,Arrowhead Research Corporation Reports Q3 EPS of $(0.23),2013-08-07 16:26:00-04:00,ARWR,neutral
98754.0,Arrowhead Begins Phase 1 Trial of RNAi Therapeutic ARC-520 for Treatment of Chronic Hepatitis B Infection,2013-07-23 07:38:00-04:00,ARWR,neutral
98755.0,Arrowhead Files to Begin Phase 1 Trial of RNAi Therapeutic,2013-05-28 07:31:00-04:00,ARWR,neutral
98756.0,Arrowhead Research Corporation Reports Q2 EPS of $(0.41),2013-05-09 16:27:00-04:00,ARWR,neutral
98757.0,UPDATE: Arrowhead Prices $36M Private Offering  at $1.83 per Share,2013-04-29 17:02:00-04:00,ARWR,positive
98758.0,Arrowhead Prices $36M Private Offering,2013-04-29 17:02:00-04:00,ARWR,neutral
98759.0,Arrowhead to Host Analyst Event Today to Discuss Chronic Hepatitis B Treatment,2013-03-25 07:21:00-04:00,ARWR,neutral
98760.0,Arrowhead Wins Notice of Patent Allowance for New Protease Sensitive Masking Chemistry for DPC siRNA Delivery System,2013-02-28 07:24:00-05:00,ARWR,positive
98761.0,Benzinga's Small Cap Movers for Tuesday February 26 2013,2013-02-26 20:35:00-05:00,ARWR,neutral
98762.0,Arrowhead Research Prices 1.65M Units at $2.12/Unit,2013-01-25 09:35:00-05:00,ARWR,neutral
98763.0,"Arrowhead Announces Proposed Stock, Warrants Offering",2013-01-24 16:13:00-05:00,ARWR,neutral
98764.0,Arrowhead Research Corporation Reports Q4 EPS of $(0.43),2012-12-20 16:03:00-05:00,ARWR,neutral
98765.0,Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics ,2012-12-18 07:09:00-05:00,ARWR,positive
98766.0,Arrowhead Prices 1.8M Units at $2.26/Unit,2012-12-07 09:26:00-05:00,ARWR,neutral
98767.0,Arrowhead Research Corporation Announces Proposed Public Offering of Common Stock and Warrants  ,2012-12-06 16:32:00-05:00,ARWR,neutral
98768.0,Arrowhead Research Receives Notice of Patent Allowance for New Formulation of DPC siRNA Delivery System Showing 500-Fold Increase in Potency,2012-10-16 09:53:00-04:00,ARWR,positive
98769.0,Stocks Hitting 52-Week Lows,2012-10-11 10:32:00-04:00,ARWR,negative
98770.0,A Peek Into The Market Before The Trading Starts,2012-08-14 07:19:00-04:00,ARWR,neutral
98771.0,Arrowhead Enters into Antibody Candidate Evaluation Agreement with Merck   ,2012-08-14 07:05:00-04:00,ARWR,positive
98772.0,"Arrowhead Researchoration Reports Q3 EPS $-0.71; Revenues $47,917",2012-08-13 16:04:00-04:00,ARWR,neutral
98773.0,"Arrowhead Sells 2.3M Shares, 1.7M Warrants for $6.2M",2012-08-13 09:41:00-04:00,ARWR,positive
98774.0,Arrowhead Pops 7% on First Patient Dosing of Adipotide,2012-07-11 10:40:00-04:00,ARWR,neutral
98775.0,A Peek Into The Market Before The Trading Starts,2012-07-11 07:21:00-04:00,ARWR,neutral
98776.0,Arrowhead Announces Dosing of First Patient with Anti-Obesity Treatment Adipotide® in a Phase 1 Clinical Trial   ,2012-07-11 07:00:00-04:00,ARWR,neutral
98777.0,"Arrowhead Announces New Study Demonstrating Rapid Improvement in Pro-Diabetic Metabolic Markers with Anti-Obesity Drug Candidate, Adipotide®   ",2012-06-26 09:06:00-04:00,ARWR,positive
98778.0,Arrowhead Research Advances ARC-520 into IND-Enabling Studies for the Treatment of Hepatitis B and Provides Guidance on Development Timeline   ,2012-06-06 07:01:00-04:00,ARWR,neutral
98779.0,4 Smaller Alternatives to Big Pharma Obesity Treatments,2012-05-25 13:17:00-04:00,ARWR,neutral
98780.0,Arrowhead Research Corporation Acquires Alvos Therapeutics and Proprietary Library of Targeting Peptides   ,2012-04-11 07:11:00-04:00,ARWR,neutral
98781.0,A Peek Into The Market Before The Trading Starts,2012-03-07 07:16:00-05:00,ARWR,neutral
98782.0,Arrowhead Releases White Paper on Hepatitis B Virus and Potential RNAi Treatment   ,2012-03-07 07:05:00-05:00,ARWR,neutral
98783.0,Arrowhead Releases White Paper on Hepatitis B Virus and Potential RNAi Treatment,2012-03-07 07:03:00-05:00,ARWR,neutral
98784.0,Arrowhead Research Corporation and Axolabs GmbH Enter into Strategic Alliance and Master Services Agreement for RNAi Therapeutics   ,2012-03-05 07:01:00-05:00,ARWR,positive
98785.0,Alnylam and Arrowhead Form Collaboration and Licensing Agreement   ,2012-01-05 08:05:00-05:00,ARWR,positive
98786.0,Arrowhead Announces FDA Clearance to Initiate Adipotide Phase I Clinical Trial,2012-01-04 07:30:00-05:00,ARWR,neutral
98787.0,Arrowhead Research Announces 1-for-10 Reverse Stock Split   ,2011-11-16 16:01:00-05:00,ARWR,neutral
98788.0,"Arrowhead Research Hits New 52-Week High, $1.19",2011-11-10 09:41:00-05:00,ARWR,neutral
98789.0,Arrowhead Research Spiking Higher on Heavy Volume,2011-11-10 09:36:00-05:00,ARWR,neutral
98790.0,Arrowhead Research Subsidiary Ablaris Therapeutics Data Published in Science Translational Medicine Demonstrates Weight Loss in Obese Monkeys   ,2011-11-10 09:33:00-05:00,ARWR,negative
98791.0,Vascular Research Further Validates the Drug Development Programs of Arrowhead Research Subsidiary Ablaris Therapeutics and Alvos Therapeutics  ,2011-11-02 16:04:00-04:00,ARWR,positive
98792.0,Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer  ,2011-10-27 07:14:00-04:00,ARWR,neutral
98793.0,Arrowhead Research Corporation Acquires Roche RNA Assets and Site  ,2011-10-24 06:49:00-04:00,ARWR,positive
98794.0,Arrowhead Research Corporation Completes $5.5 Million Private Placement,2011-10-04 07:00:00-04:00,ARWR,neutral
98795.0,Arrowhead Research Making Late-Day Run	,2011-07-29 15:26:00-04:00,ARWR,neutral
98796.0,The Next Big Breakout Stock,2011-07-26 11:52:00-04:00,ARWR,neutral
98797.0,Arrowhead Receives Additional 180 Day Grace Period to Comply with the NASDAQ $1.00 Minimum Bid Requirement,2011-06-09 07:02:00-04:00,ARWR,positive
98798.0,"Top Chemical Manufacturing Stocks pick to buy- FSI, VHI, SMG, LXU, TNH, SHI, BAK, CF, RTK, GRA, NANX…",2011-05-09 04:45:00-04:00,ARWR,positive
98799.0,Arrowhead Reports Q1 EPS of $(0.02),2011-02-10 16:49:00-05:00,ARWR,neutral
98800.0,Arrowhead Increases Investment in Calando Pharmaceuticals,2011-01-18 07:58:00-05:00,ARWR,neutral
98801.0,8 Penny Stocks Get Delisting Warning,2011-01-04 07:00:00-05:00,ARWR,negative
98802.0,Arrowhead Reports Revenue of $181k,2010-12-22 16:03:00-05:00,ARWR,neutral
98803.0,Arrowhead CEO Comments on $4.5M Alliance Between Unidym and Samsung Electronics   ,2010-12-09 08:40:00-05:00,ARWR,neutral
98804.0,NanoIntegris and Unidym Execute Global Distribution Agreement ,2010-10-27 13:03:00-04:00,ARWR,positive
98805.0,Arrowhead CEO Provides Update on Company Strategy ,2010-09-29 07:27:00-04:00,ARWR,neutral
98806.0,Arrowhead Reports Fiscal 2010 Third Quarter Financial Results,2010-08-12 16:12:00-04:00,ARWR,neutral
98807.0,"Stocks That Crossed 52-Week Highs (ALXA, AETI, ARWR, CALP, CAVM)",2010-04-27 15:22:00-04:00,ARWR,neutral
